^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Salivary Gland Cancer |
| Drug: | ACE1702 (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1006P-ACE1702, a first-in-class, off-the-shelf, selected natural killer cell [oNK] product using antibody cell conjugation technology [ACC], with pre-clinical and early clinical activity in HER2 <3+ tumors
Published date:
09/13/2021
Excerpt:
Up to 36 pts with advanced HER2 IHC ≥ 2+ tumors are to be enrolled to receive low dose lymphodepletion [LD] followed by an assigned level of escalating ACE1702 doses 0.3-15 billion [B] cells/cycle….At 3B cells/cycle, 1 pt with HER2 2+ refractory salivary gland tumor achieved a partial response.
Trial ID:
